Candel Therapeutics, Inc. · Brief

Next report

8 days

Nov 12 · before openest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

0 of 8≥ implied

Mar 13 '25±15.2%▲+10.20%×0.67

May 13 '25±15.8%▲+7.68%×0.49

Aug 14 '25±14.1%▼−5.63%×0.40

Q3 FY25±26.0%▼−10.74%×0.41

Nov 13 '25±13.7%▼−6.30%×0.46

Q1 FY26±9.8%▼−2.35%×0.24

May 14 '26±38.6%▼−0.34%×0.01

Q2 FY26±12.0%▲+10.49%×0.87

quarterimplied−40%0+40%realized×

Q2 FY26±12.0%▲+10.49%×0.87

May '26±38.6%▼−0.34%×0.01

Q1 FY26±9.8%▼−2.35%×0.24

Nov '25±13.7%▼−6.30%×0.46

Q3 FY25±26.0%▼−10.74%×0.41

Aug '25±14.1%▼−5.63%×0.40

2 older reports

May '25±15.8%▲+7.68%×0.49

Mar '25±15.2%▲+10.20%×0.67

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 12 report · est.

Bull2 of 3

+18.19%ten largest reporting managers increased aggregate shares held over the latest quarter13F · Jun 30 '26

138managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2

10managers whose positions together make up four fifths of the reported value13F · Jun 30 '26

0.19%State Street SPDR S and P Biotech ETF's share of its assetsN-PORT · Jun 30 '26

AI captions · Sep 27 '26once per report · top 2 per case

CADL report session

No linked exposure.

Oct 30impliedImplied move: ±51.5% into Nov 12 earnings (Oct 30 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.